Molecular diagnosis of ATP-binding cassette transporter-related diseases

Expert Review of Molecular Diagnostics

Volumn 5, Issue 5, 2005, Pages 755-767

  Schuierer, Marion M ^a   Langmann, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

ATP binding cassette transporters; Cystic fibrosis; Familial HDL deficiency; Molecular diagnostics; Multidrug resistance; Pharmacogenetics; Polymorphisms

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; MESSENGER RNA;

CYSTIC FIBROSIS; DRUG RESISTANCE; FLUORESCENCE; GENE MUTATION; HUMAN; MONOGENIC DISORDER; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETINA DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TANGIER DISEASE;

EID: 25144442626     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.5.5.755     Document Type: Review

References (125)

1. Higgins CF. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8, 67-113 (1992).
2. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the α- and β-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1, 945-951 (1982).
3. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33, 475-479 (2001).
4. Ueda K, Matsuo M, Tanabe K et al. Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins. Biochim. Biophys. Acta 1461, 305-313 (1999).
5. Szabo K, Szakacs G, Hegeds T, Sarkadi B. Nucleotide occlusion in the human cystic fibrosis transmembrane conductance regulator. Different patterns in the two nucleotide binding domains. J. Biol. Chem. 274, 12209-12212 (1999).
6. + channels. Biochim. Biophys. Acta 1461, 285-303 (1999).
7. Szakacs G, Langmann T, Ozvegy C et al. Characterization of the ATPase cycle of human ABCA1: implications for its function as a regulator rather than an active transporter. Biochem. Biophys. Res. Commun. 288, 1258-1264 (2001).
8. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
9. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
10. Ambudkar SV, Gottesman MM. ABC transporters: biochemical, cellular and molecular aspects. In: Methods in Enzymology (Volume 292). Academic Press, NY, USA (1998).
11. Ho GT, Nimmo ER, Tenesa A et al. Allelic variations of the multi-drug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128, 288-296 (2005).
12. Mace S, Cousin E, Ricard S et al. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol. Dis. 18, 119-125 (2005).
13. Bodzioch M, Orso E, Klucken J et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 22, 347-351 (1999).
14. Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 22, 336-345 (1999).
15. Rust S, Rosier M, Funke H et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet. 22, 352-355 (1999).
16. Asztalos BF, Brousseau ME, McNamara JR et al. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 156, 217-225 (2001).
17. Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J. Clin. Invest. 106, 1205-1207 (2000).
18. Clee SM, Kastelein JJ, van Dam M et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J. Clin. Invest. 106, 1263-1270 (2000).
19. Clee SM, Zwinderman AH, Engert JC et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 103, 1198-1205 (2001).
20. Schmitz G, Kaminski WE. ABC transporters and cholesterol metabolism. Front. Biosci. 6, D505-D514 (2001).
21. Schmitz G, Langmann T. Structure, function and regulation of the ABC1 gene product. Curr. Opin. Lipidol. 12, 129-140 (2001). Review describing molecular functions of ABCA1 including phenotypic characteristics.
22. Probst MC, Thumann H, Aslanidis C et al. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 175, 269-279 (2004).
23. Fasano T, Bocchi L, Pisciotta L, Bertolini S, Calandra S. Denaturing high-performance liquid chromatography in the detection of ABCA1 gene mutations in familial HDL deficiency. J. Lipid Res. 46, 817-822 (2005).
24. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler. Thromb. Vasc. Biol. 23, 1322-1332 (2003).
25. Lapicka-Bodzioch K, Bodzioch M, Krull M et al. Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. Biochim. Biophys. Acta 1537, 42-48 (2001).
26. Allikmets R. Simple and complex ABCR: genetic predisposition to retinal disease. Am. J. Hum. Genet. 67, 793-799 (2000). Comprehensive review of molecular diagnostics of ABCA4 mutations causing different retinal disorders.
27. Allikmets R, Singh N, Sun H et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nature Genet. 15, 236-246 (1997).
28. Azarian SM, Travis GH. The photoreceptor rim protein is an ABC transporter encoded by the gene for recessive Stargardt's disease (ABCR). FEBS Lett. 409, 247-252 (1997).
29. Illing M, Molday LL, Molday RS. The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily. J. Biol. Chem. 272, 10303-10310 (1997).
30. Cremers FP, van de Pol DJ, van Driel M et al. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt's disease gene ABCR. Hum. Mol. Genet. 7, 355-362 (1998).
31. Rozet JM, Gerber S, Souied E et al. Spectrum of ABCR gene mutations in autosomal recessive macular dystrophies. Eur. J. Hum. Genet. 6, 291-295 (1998).
32. Martinez-Mir A, Paloma E, Allikmets R et al. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. Nature Genet. 18, 11-12 (1998).
33. Rozet JM, Gerber S, Ghazi I et al. Mutations of the retinal specific ATP binding transporter gene (ABCR) in a single family segregating both autosomal recessive retinitis pigmentosa RP19 and Stargardt disease: evidence of clinical heterogeneity at this locus. J. Med. Genet. 36, 447-451 (1999).
34. Rozet JM, Gerber S, Souied E et al. The ABCR gene: a major disease gene in macular and peripheral retinal degenerations with onset from early childhood to die elderly. Mol. Genet. Metab. 68, 310-315 (1999).
35. Allikmets R. Molecular genetics of age-related macular degeneration: current status. Eur. J. Ophthalmol. 9, 255-265 (1999).
36. Rivera A, White K, Stohr H et al. A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. Am. J. Hum. Genet. 67, 800-813 (2000).
37. Simonelli F, Testa F, de Crecchio G et al. New ABCR mutations and clinical phenotype in Italian patients with Stargardt disease. Invest. Ophthalmol. Vis. Sci. 41, 892-897 (2000).
38. Cremonesi L, Stenirri S, Fermo I et al. Denaturing HPLC analysis of DNA deletions and insertions. Hum. Mutat. 22, 98-102 (2003).
39. Fumagalli A, Ferrari M, Soriani N et al. Mutational scanning of the ABCR gene with double-gradient denaturing-gradient gel electrophoresis (DG-DGGE) in Italian Stargardt disease patients. Hum. Genet. 109, 326-338 (2001).
40. Schmidt S, Postel EA, Agarwal A et al. Detailed analysis of allelic variation in the ABCA4 gene in age-related maculopathy. Invest. Ophthalmol. Vis. Sci. 44, 2868-2875 (2003).
41. Stenirri S, Fermo I, Battistella S et al. Denaturing HPLC profiling of the ABCA4 gene for reliable detection of allelic variations. Clin. Chem. 50, 1336-1343 (2004).
42. Jaakson K, Zernant J, Kulm M et al. Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum. Mutat. 22, 395-403 (2003). Reports the fabrication and use of a DNA microarray to detect ABCA4 mutations.
43. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. 79, S145-S166 (1999).
44. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol. Rev. 79, S23-S45 (1999).
45. Cohn JA, Friedman KJ, Noone PG et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N. Engl. J. Med. 339, 653-658 (1998).
46. Pignatti PF, Bombieri C, Marigo C, Benetazzo M, Luisetti M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum. Mol. Genet. 4, 635-639 (1995).
47. Dean M, White MB, Amos J et al. Multiple mutations in highly conserved residues are found in mildly affected cystic fibrosis patients. Cell 61, 863-870 (1990).
48. Dequeker E, Cuppens H, Dodge J et al. Recommendations for quality improvement in genetic testing for cystic fibrosis. European Concerted Action on Cystic Fibrosis. Eur. J. Hum. Genet. 8(Suppl. 2), S2-S24 (2000).
49. Galvin P, Clarke LA, Harvey S, Amaral MD. Microarray analysis in cystic fibrosis. J. Cyst. Fibros. 3(Suppl. 2), 29-33 (2004).
50. Richards CS, Grody WW. Prenatal screening for cystic fibrosis: past, present and future. Expert Rev. Mol. Diagn. 4, 49-62 (2004). Well-written review covering important aspects of molecular diagnosis of cystic fibrosis.
51. Ibarreta D, Elles R, Cassiman JJ, Rodriguez-Cerezo E, Dequeker E. Towards quality assurance and harmonization of genetic testing services in the European Union. Nature Biotechnol. 22, 1230-1235 (2004).
52. Thomas PM, Cote GJ, Wohllk N et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426-429 (1995).
53. Aguilar-Bryan L, Clement JP, Gonzalez G et al. Toward understanding the assembly and structure of KATP channels. Physiol. Rev. 78, 227-245 (1998).
54. Goksel DL, Fischbach K, Duggirala R et al. Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum. Genet. 103, 280-285 (1998).
55. Laukkanen O, Pihlajamaki J, Lindstrom J et al. Polymorphisms of the SUR1 (ABCC8) and KiR6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. J. Clin. Endocrinol. Metab. 89, 6286-6290 (2004).
56. Reis AF, Ye WZ, Dubois-Laforgue D et al. Association of a variant in exon 31 of the sulfonylurea receptor 1 (SUR1) gene with Type 2 diabetes mellitus in French Caucasians. Hum. Genet. 107, 138-144 (2000).
57. Bienengraeber M, Olson TM, Selivanov VA et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nature Genet. 36, 382-387 (2004).
58. Langmann T, Mauerer R, Zahn A et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin. Chem. 49, 230-238 (2003). First description of mRNA expression profiling of all human ATP-binding cassette (ABC) transporters using quantitative real-time reverse transcriptase PCR.
59. Kaminski WE, Piehler A, Pullmann K et al. Complete coding sequence, promoter region, and genomic structure of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun. 281, 249-258 (2001).
60. Tanaka Y, Yamada K, Zhou CJ et al. Temporal and spatial profiles of ABCA2-expressing oligodendrocytes in the developing rat brain. J. Comp. Neurol. 455, 353-367 (2003).
61. Zhou C, Zhao L, Inagaki N et al. Atp-binding cassette transporter ABC2/ABCA2 in the rat brain: a novel mammalian lysosome-associated membrane protein and a specific marker for oligodendrocytes but not for myelin sheaths. J. Neurosci. 21, 849-857 (2001).
62. Laing NM, Belinsky MG, Kruh GD et al. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 58, 1332-1337 (1998).
63. Vulevic B, Chen Z, Boyd JT et al. Cloning and characterization of human adenosine 5′-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res. 61, 3339-3347 (2001).
64. Boonstra R, Timmer-Bosscha H, Echten-Arends J et al. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br. J. Cancer 90, 2411-2417 (2004).
65. Wang Y, Yamada K, Tanaka Y, Ishikawa K, Inagaki N. Expression of ABCA2 protein in human vestibular schwannoma and peripheral nerve. J. Neurol. Sci. 232, 59-63 (2005).
66. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468-7485 (2003). Detailed overview of ABCB1/MDR1 in human disease.
67. Higgins CF. Molecular basis of multi-drug resistance mediated by P-glycoprotein. Curr. Opin. Biotechnol. 2, 278-281 (1991).
68. Chan HS, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325, 1608-1614 (1991).
69. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl Cancer Inst. 84, 1486-1491 (1992).
70. Pirker R, Wallner J, Geissler K et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl Cancer Inst. 83, 708-712 (1991).
71. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333, 1380-1385 (1995).
72. Fisher GA, Sikic BI. Clinical studies with modulators of multi-drug resistance. Hematol. Oncol. Clin. North Am. 9, 363-382 (1995).
73. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 3, 833-838 (2004).
74. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multi-drug resistant human lung cancer cell line. Science 258, 1650-1654 (1992).
75. Kruh GD, Gaughan KT, Godwin A, Chan A. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J. Natl Cancer Inst. 87, 1256-1258 (1995).
76. Nooter K, Westerman AM, Flens MJ et al. Expression of the multi-drug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1, 1301-1310 (1995).
77. Cui Y, Konig J, Buchholz JK et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multi-drug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55, 929-937 (1999).
78. Hinoshita E, Uchiumi T, Taguchi K et al. Increased expression of an ATP-binding cassette superfamily transporter, multi-drug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. 6, 2401-2407 (2000).
79. Narasaki F, Oka M, Nakano R et al. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem. Biophys. Res. Commun. 240, 606-611 (1997).
80. Nies AT, Konig J, Pfannschmidt M et al. Expression of the multi-drug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 94, 492-499 (2001).
81. Schaub TP, Kartenbeck J, Konig J et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. 10, 1159-1169 (1999).
82. Young LC, Campling BG, Voskoglou-Nomikos T et al. Expression of multi-drug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 5, 673-680 (1999).
83. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multi-drug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 7, 1798-1804 (2001).
84. Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multi-drug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57, 3537-3547 (1997).
85. Schuetz JD, Connelly MC, Sun D et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Med. 5, 1048-1051 (1999).
86. Wijnholds J, Mol CA, van Deemter L et al. Multi-drug resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl Acad. Sci. USA 20(97), 7476-7481 (2000).
87. Wielinga P, Hooijberg JH, Gunnarsdottir S et al. The human multi-drug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 65, 4425-4430 (2005).
88. Longhurst TJ, O'Neill GM, Harvie RM, Davey RA. The anthracycline resistance-associated (ara) gene, a novel gene associated with multi-drug resistance in a human leukaemia cell line. Br. J. Cancer 74, 1331-1335 (1996).
89. Bera TK, Lee S, Salvatore G, Lee B, Pastan I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. 7, 509-516 (2001).
90. Bera TK, Iavarone C, Kumar V et al. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl Acad. Sci. USA 99, 6997-7002 (2002).
91. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multi-drug resistance. Cancer Res. 58, 5337-5339 (1998).
92. Doyle LA, Yang W, Abruzzo LV et al. A multi-drug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665-15670 (1998).
93. Miyake K, Mickley L, Litman T et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13 (1999).
94. Ross DD, Yang W, Abruzzo LV et al. Atypical multi-drug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl Cancer Inst. 91, 429-433 (1999).
95. Benderra Z, Faussat AM, Sayada L et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10, 7896-7902 (2004).
96. Suvannasankha A, Minderman H, O'Loughlin KL et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br. J. Haematol. 127, 392-398 (2004).
97. Uggla B, Stahl E, Wagsater D et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk. Res. 29, 141-146 (2005).
98. Szakacs G, Annereau JP, Lababidi S et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129-137 (2004). Study reporting the correlation of ABC transporter mRNA expression and multidrug resistance in cancer cell lines.
99. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 22, 6497-6507 (2003).
100. Annereau JP, Szakacs G, Tucker CJ et al. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multi-drug resistance. Mol. Pharmacol. 66, 1397-1405 (2004). Article demonstrating the use of DNA microarrays to analyze ABC transporter expression in tumor cell lines.
101. Huang Y, Anderle P, Bussey KJ et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 64, 4294-4301 (2004). Article demonstrating the use of DNA microarrays to analyze ABC transporter expression in tumor cell lines.
102. Gillet JP, Efferth T, Steinbach D et al. Microarray-based detection of multi-drug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 64, 8987-8993 (2004). Article demonstrating the use of DNA microarrays to analyze ABC transporter expression in tumor cell lines.
103. Coley HM, Verrill MW, Gregson SE et al. Incidence of P-glycoprotein overexpression and multi-drug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer 36, 881-888 (2000).
104. Flens MJ, Izquierdo MA, Scheffer GL et al. Immunochemical detection of the multi-drug resistance-associated protein MRP in human multi-drug resistant tumor cells by monoclonal antibodies. Cancer Res. 54, 4557-4563 (1994).
105. Okochi E, Iwahashi T, Tsuruo T. Monoclonal antibodies specific for P-glycoprotein. Leukemia 11, 1119-1123 (1997).
106. + cells. Eur. J. Haematol. 71, 119-123 (2003).
107. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein- mediated multi-drug resistance with a monoclonal antibody. Proc. Natl Acad. Sci. USA 89, 5824-5828 (1992).
108. Kostakoglu L, Guc D, Canpinar H et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J. Nucl. Med. 39, 1191-1197 (1998).
109. Taki J, Sumiya H, Asada N et al. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J. Nucl. Med. 39, 1179-1184 (1998).
110. Beck WT, Grogan TM. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 11, 1107-1109 (1997).
111. Kim M, Turnquist H, Jackson J et al. The multi-drug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin. Cancer Res. 8, 22-28 (2002).
112. Marie JP, Legrand O, Perrot JY et al. Measuring multi-drug resistance expression in human malignancies: elaboration of consensus recommendations. Semin. Hematol. 34, 63-71 (1997).
113. Petriz J, Garcia-Lopez J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 11, 1124-1130 (1997).
114. Hollo Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta 1191, 384-388 (1994).
115. Homolya L, Hollo M, Muller M, Mechetner EB, Sarkadi B. A new method for a quantitative assessment of P-glycoprotein-related multi-drug resistance in tumour cells. Br. J. Cancer 73, 849-855 (1996). First description of a quantitative functional assay to monitor ABCB1-related drug resistance.
116. Karaszi E, Jakab K, Homolya L et al. Calcein assay for multi-drug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br. J. Haematol. 112, 308-314 (2001).
117. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
118. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multi-drug resistance-associated proteins. J. Natl Cancer Inst. 92, 1295-1302 (2000).
119. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today 6, 835-839 (2001).
120. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Top. Med. Chem. 4, 1385-1398 (2004).
121. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multi-drug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000). Excellent report on the systematic identification of ABCB1 single nucleotide polymorphisms and their functional consequences.
122. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
123. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multi-drug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36 (2002).
124. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185 (2004). State-of-the-art review of ABCB1 pharmacogenetics.
125. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol. Cancer Ther. 2, 685-698 (2003).